FUNDAMENTALS · Fundamentals · GB Healthcare

AstraZeneca (AZN) Fundamentals 2026 — P/E 25.2x, Revenue Analysis | SniperIQ

AstraZeneca (AZN) is a GB-listed Healthcare company in Drug Manufacturers - General with a market capitalization of

31.3B, trading at
69.51 on the NYSE. This SniperIQ fundamentals page covers AstraZeneca's valuation (P/E 25.2x, P/B 5.6x), profitability (net margin 17.2%), revenue ($58.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
31.3B
P/E (TTM)25.2x
Net Margin17.2%
Revenue (FY25)$58.7B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is AstraZeneca's market cap?

AstraZeneca (AZN) has a market capitalization of approximately

31.3B, trading at
69.51 on the NYSE. Market cap moves with the live share price.

What is AstraZeneca's P/E ratio?

AstraZeneca's trailing twelve-month P/E ratio is 25.2x, with a price-to-book (P/B) of 5.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is AstraZeneca?

AstraZeneca runs a net profit margin of 17.2%, a gross margin of 79.7%, and an operating margin of 23.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does AstraZeneca generate?

AstraZeneca reported revenue of $58.7B for fiscal year 2025, with net income of

0.3B and earnings per share (EPS) of 13.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does AstraZeneca pay a dividend?

AstraZeneca offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is AstraZeneca financially healthy?

AstraZeneca carries a debt-to-equity ratio of 0.72x and a current ratio of 0.91x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is AstraZeneca a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AstraZeneca (AZN) the key facts are: market cap

31.3B, P/E 25.2x, revenue $58.7B, 52-week range 142.98-212.71. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track AstraZeneca's full fundamentals live

Get AstraZeneca's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Samil Pharmaceutical (000520) fundamentals · Shinhung (004080) fundamentals · BML (4694) fundamentals · Danaher (DHR) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons